ORIC News
Archived Headlines
- US IPO Weekly Recap: ORIC pops 61% and SPACs make a comeback 04/24/20
- ORIC Pharmaceuticals prices upsized IPO at $16, the high end of the range 04/23/20
- Venture firm The Column Group notches fifth biotech IPO in two years 04/23/20
- Oncology biotech ORIC Pharmaceuticals ups proposed share offering by 25% ahead of $94 million IPO 04/23/20
- Oncology biotech ORIC Pharmaceuticals sets terms for $75 million IPO 04/20/20
See more
2020 biotech IPOs now average an 80% return from their offer price
The 2020 US biotech IPO class closed Wednesday with an 80% average return from the offering price, a historic run-up for the year's 23 development-stage drug developers. The group has averaged a 36% pop on day one, and then 35% from there. Biotechs make up 70%...read more
US IPO Week Ahead: Online insurance platform plans largest US IPO since February
Updated Monday 5/18 The largest US IPO since February, a SPAC, and a medical device company IPO are on the calendar for the week ahead. SelectQuote (SLQT), an online platform for comparing and purchasing insurance, plans to raise...read more
The IPO market’s slowest spring since the financial crisis
The 2020 IPO market saw its slowest March and April in over a decade, as volatility essentially shut the IPO window. Just seven IPOs priced during the past two months, a 70% decline from the 15-year average of 23 IPOs. ...read more
US IPO Week Ahead: The IPO pipeline is active in a 1 IPO week
Updated on 4/27/2020. One biotech and two SPACs are on the calendar for the week ahead. The IPO market is showing some early signs of opening up. Recent biotech IPOs have had strong debuts, SPAC activity has picked up, and a few deals in the...read more